About Inozyme Pharma
Inozyme Pharma is a company based in Cambridge (United States) founded in 2016 by Axel Bolte was acquired by BioMarin Pharmaceutical in May 2025.. Inozyme Pharma has raised $116.4 million across 2 funding rounds from investors including BioMarin Pharmaceutical, TD Securities and RA Capital. The company has 59 employees as of December 31, 2023. Inozyme Pharma operates in a competitive market with competitors including Alnylam, Ultragenyx, BioMarin Pharmaceutical, Ardelyx and Mirum Pharmaceuticals, among others.
- Headquarter Cambridge, United States
- Employees 59 as on 31 Dec, 2023
- Founders Axel Bolte
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
$102.02 M43as on Dec 31, 2024
-
EBITDA
$-104.03 M-38as on Dec 31, 2024
-
Total Equity Funding
$116.4 M (USD)
in 2 rounds
-
Latest Funding Round
$67.4 M (USD), Series A
Apr 10, 2019
-
Investors
BioMarin Pharmaceutical
& 9 more
-
Employee Count
59
as on Dec 31, 2023
-
Acquired by
BioMarin Pharmaceutical
(May 16, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of Inozyme Pharma
Inozyme Pharma has successfully raised a total of $116.4M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $67.4 million completed in April 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series A — $67.4M
-
First Round
First Round
(15 Nov 2017)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr, 2019 | Amount | Series A - Inozyme Pharma | Valuation | Sofinnova Investments , Pivotal bioVenture Partners | |
| Nov, 2017 | Amount | Series A - Inozyme Pharma | Valuation | Longitude Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Inozyme Pharma
Inozyme Pharma has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include BioMarin Pharmaceutical, TD Securities and RA Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech funding, drug development support, and investment in life sciences.
|
Founded Year | Domain | Location | |
|
Early-stage and late-stage biotech and finance companies are funded.
|
Founded Year | Domain | Location | |
|
Private equity firm focused on life science sector
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Inozyme Pharma
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Inozyme Pharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Inozyme Pharma Comparisons
Competitors of Inozyme Pharma
Inozyme Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alnylam, Ultragenyx, BioMarin Pharmaceutical, Ardelyx and Mirum Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical.
|
|
| domain | founded_year | HQ Location |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for rare genetic diseases
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Inozyme Pharma
Frequently Asked Questions about Inozyme Pharma
When was Inozyme Pharma founded?
Inozyme Pharma was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Where is Inozyme Pharma located?
Inozyme Pharma is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Who is the current CEO of Inozyme Pharma?
Axel Bolte is the current CEO of Inozyme Pharma. They have also founded this company.
Is Inozyme Pharma a funded company?
Inozyme Pharma is a funded company, having raised a total of $116.4M across 2 funding rounds to date. The company's 1st funding round was a Series A of $49M, raised on Nov 15, 2017.
How many employees does Inozyme Pharma have?
As of Dec 31, 2023, the latest employee count at Inozyme Pharma is 59.
What does Inozyme Pharma do?
Developer of treatments for rare and debilitating metabolic diseases. The companys product line include INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy to increase PPi and adenosine, enabling the potential treatment of multiple diseases caused by deficiencies in metabolites.
Who are the top competitors of Inozyme Pharma?
Inozyme Pharma's top competitors include Alnylam, UniQure and BioMarin Pharmaceutical.
Who are Inozyme Pharma's investors?
Inozyme Pharma has 10 investors. Key investors include BioMarin Pharmaceutical, TD Securities, RA Capital, Sofinnova, and Rock Springs Capital.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.